Lista de obras -

Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial

artículo científico publicado en 2013

Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial

artículo científico publicado en 2009

Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: A First Approach for the Study of Pharmacologic Sanctuaries

scientific article published on 31 August 2020

Characterization of binding of raltegravir to plasma proteins

artículo científico publicado en 2013

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir

artículo científico publicado en 2005

Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort

scientific article published on 05 August 2019

Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

artículo científico publicado en 2016

Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration

artículo científico publicado en 2006

Dolutegravir Cerebrospinal Fluid Diffusion in HIV-1-Infected Patients with Central Nervous System Impairment

artículo científico publicado en 2019

Dose regimen of favipiravir for Ebola virus disease

artículo científico publicado en 2014

Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.

artículo científico

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

artículo científico publicado en 2016

Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial

artículo científico publicado en 2020

Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.

artículo científico publicado en 2007

Erratum for Madelain et al., "Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses".

artículo científico publicado en 2017

Evidence-based therapeutic drug monitoring for indinavir

artículo científico publicado en 2011

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

artículo científico publicado en 2016

Falsely elevated whole blood tacrolimus concentrations due to interference in an affinity column-mediated immunoassay method on Xpand dimension.

artículo científico publicado en 2009

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses

artículo científico publicado en 2016

Favipiravir for children with Ebola

artículo científico publicado en 2015

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

artículo científico publicado en 2017

French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults

artículo científico publicado en 2014

High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study

artículo científico publicado en 2015

High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial

artículo científico publicado en 2009

High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy

artículo científico publicado en 2005

Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda ⬇️

artículo científico publicado el 26 de julio de 2011

Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients

artículo científico publicado en 2007

Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients

artículo científico publicado en 2008

Interaction between tacrolimus and fumagillin in two kidney transplant recipients.

artículo científico publicado en 2006

Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient

artículo científico publicado en 2006

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus

artículo científico publicado en 2004

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

artículo científico publicado en 2004

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

artículo científico publicado en 2010

Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease

artículo científico publicado en 2006

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

artículo científico publicado en 2008

Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial ⬇️

artículo científico publicado el 15 de septiembre de 2010

Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy

scientific article published on 01 January 2006

Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure

artículo científico publicado en 2011

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial

scholarly article by Maryline Bonnet et al published April 2013 in Lancet Infectious Diseases

Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies

artículo científico publicado en 2003

Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients

artículo científico publicado en 2011

Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study

artículo científico publicado en 2014

Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review

artículo científico publicado en 2018

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients ⬇️

artículo científico publicado el 23 de octubre de 2010

Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state

artículo científico publicado en 2013

Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg.

artículo científico publicado en 2012

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)

artículo científico publicado en 2014

Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy

artículo científico publicado en 2005

Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.

artículo científico publicado en 2007

Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.

artículo científico publicado en 2012

Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia

artículo científico publicado en 2007

Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence

artículo científico publicado en 2012

Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen

artículo científico publicado en 2008

Presence of Lamivudine or Emtricitabine Is Associated with Reduced Emergence of Nonnucleoside Reverse Transcriptase Inhibitor Mutations in an Efavirenz-Based Intermittent Antiretroviral Treatment Regimen ⬇️

artículo científico publicado el 27 de diciembre de 2011

Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone

artículo científico publicado en 2009

Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy

artículo científico publicado en 2009

Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection

artículo científico publicado en 2009

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir

artículo científico publicado en 2015

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam

artículo científico publicado en 2014

Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir

artículo científico publicado en 2007

Residual HIV-1 RNA and HIV-1 Dna Production in the Genital Tract Reservoir of Women Treated with Haart: The Prospective Anrs Ep24 Gynodyn Study ⬇️

artículo científico publicado el 1 de enero de 2011

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen ⬇️

artículo científico publicado el 13 de noviembre de 2010

Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).

artículo científico publicado en 2013

Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.

artículo científico publicado en 2004

Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results

artículo científico publicado en 2007

Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

artículo científico publicado en 2006

Short Communication: Three Years Follow-Up of First-Line Antiretroviral Therapy in Cambodia: Negative Impact of Prior Antiretroviral Treatment ⬇️

artículo científico publicado el 17 de enero de 2011

Simplified Assessment of Antiretroviral Adherence and Prediction of Virological Efficacy in HIV-Infected Patients in Cambodia

artículo científico publicado en 2009

Sofosbuvir-based Regimens in HIV/HCV Coinfected Patients after Liver Transplantation: Results from the ANRS CO23 CUPILT Study

artículo científico publicado en 2017

Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients

artículo científico publicado en 2003

Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft

artículo científico publicado en 2013

Switch from Enfuvirtide to Raltegravir Lowers Plasma Concentrations of Darunavir and Tipranavir: a Pharmacokinetic Substudy of the EASIER-ANRS 138 Trial ⬇️

artículo científico publicado el 16 de mayo de 2011

Telaprevir enhances ribavirin-induced anaemia through renal function impairment

artículo científico publicado en 2014

The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers

scientific article published on 25 June 2020

Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation

artículo científico publicado en 2015

Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures

artículo científico publicado en 2004

[Evidence-based therapeutic drug monitoring of lopinavir]

artículo científico publicado en 2011

Lista de obras de

Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial

Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial

Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: A First Approach for the Study of Pharmacologic Sanctuaries

Characterization of binding of raltegravir to plasma proteins

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir

Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort

Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration

Dolutegravir Cerebrospinal Fluid Diffusion in HIV-1-Infected Patients with Central Nervous System Impairment

Dose regimen of favipiravir for Ebola virus disease

Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial

Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.

Erratum for Madelain et al., "Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses".

Evidence-based therapeutic drug monitoring for indinavir

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Falsely elevated whole blood tacrolimus concentrations due to interference in an affinity column-mediated immunoassay method on Xpand dimension.

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses

Favipiravir for children with Ebola

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults

High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study

High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial

High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy

Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda ⬇️

Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients

Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients

Interaction between tacrolimus and fumagillin in two kidney transplant recipients.

Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial ⬇️

Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy

Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial

Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies

Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients

Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study

Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients ⬇️

Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state

Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg.

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)

Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy

Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.

Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.

Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia

Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence

Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen

Presence of Lamivudine or Emtricitabine Is Associated with Reduced Emergence of Nonnucleoside Reverse Transcriptase Inhibitor Mutations in an Efavirenz-Based Intermittent Antiretroviral Treatment Regimen ⬇️

Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone

Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy

Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam

Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir

Residual HIV-1 RNA and HIV-1 Dna Production in the Genital Tract Reservoir of Women Treated with Haart: The Prospective Anrs Ep24 Gynodyn Study ⬇️

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen ⬇️

Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).

Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.

Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results

Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

Short Communication: Three Years Follow-Up of First-Line Antiretroviral Therapy in Cambodia: Negative Impact of Prior Antiretroviral Treatment ⬇️

Simplified Assessment of Antiretroviral Adherence and Prediction of Virological Efficacy in HIV-Infected Patients in Cambodia

Sofosbuvir-based Regimens in HIV/HCV Coinfected Patients after Liver Transplantation: Results from the ANRS CO23 CUPILT Study

Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients

Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft

Switch from Enfuvirtide to Raltegravir Lowers Plasma Concentrations of Darunavir and Tipranavir: a Pharmacokinetic Substudy of the EASIER-ANRS 138 Trial ⬇️

Telaprevir enhances ribavirin-induced anaemia through renal function impairment

The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers

Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation

Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures

[Evidence-based therapeutic drug monitoring of lopinavir]